News
-
-
-
PRESS RELEASE
Half-year results 2026: Strict financial discipline and a stronger cash position to enter the next growth cycle from the best possible position
Fermentalg reports stable half-year results for 2026 with growth in DHA sales and production of new EPA/DHA range. Shareholders' equity strengthened for accelerated growth. Financial autonomy targeted with promising outlook -
-
-
-
-
-
PRESS RELEASE
Revenue for the first half of 2026: EUR7.4 million // Growth in DHA sales in high value-added segments and first order of the natural blue colour
Fermentalg reports unaudited revenue for H1 2026, highlighting growth in ΩRIGINSTM lipids sales and first order of Galdieria BlueTM, aiming for €20M annual revenue -
